Cagrilintide + Tirzepatide
Stack a long-acting amylin agonist onto tirzepatide's dual GIP/GLP-1 action to push fat-loss and metabolic-marker improvement beyond either compound alone, in principle allowing lower per-drug doses for the same or better effect.
Tirzepatide already curbs appetite through two gut-hormone pathways; cagrilintide adds a <b>third, separate</b> one (amylin, a satiety hormone).
